Transforming Cancer Screening and Diagnosis
Saving and Improving Lives
3/12/2025 Press Release
PD-L1 Measured by Blood Test Reveals Important Clinical Information
Innovative blood test for early detection and diagnosis of cancer
when it matters most
Cancer Screening and Monitoring Recurrence
For all cancers
In all stages
Minimal Residual Disease
Early detection of recurrence
Companion diagnostics - not requiring tissue
Provide aggressiveness of the cancer
Provide whole tumor DNA for sequencing
Cancer Diagnostics
Monitoring Therapy
Assay applicable to all cancers
Enhance patient selection
Provide prognosis at any time
Predict treatment response
Provide companion diagnostics - not requiring tissue
Validate drug targets
Deliver high quality DNA for sequencing
Streamline Drug Development and Clinical Trials
Predict response to new therapy in ~30 days
Sequential monitoring of therapy
Clinical trials
Partnering
Licensing